Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

224.13 -9.29 (-3.98%)

Official Closing Price Updated: 7:00 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

92 93 Next >

A Must-Own Stock for Any Portfolio ↗

May 22, 2024

This company offers growth, high yield, and dividend growth.

Via The Motley Fool

2 Billion More Reasons to Buy AbbVie Stock ↗

May 22, 2024

This pharma giant just made a smart strategic acquisition.

Via The Motley Fool

3 S&P 500 Stocks That Have Proven Themselves Recession-Proof ↗

May 20, 2024

Corrections are a part of investing and investors would be smart to have these three S&P 500 stocks to buy when the inevitable happens.

Via InvestorPlace

Topics Stocks

1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165? ↗

May 20, 2024

Revenue growth during what should be a disastrous patent cliff is encouraging.

Via The Motley Fool

Topics Intellectual Property

Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch ↗

May 18, 2024

President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).

Via Benzinga

Topics Cannabis

The Analyst Verdict: AbbVie In The Eyes Of 5 Experts ↗

May 17, 2024

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,000 Today ↗

May 16, 2024

Via Benzinga

Unpacking the Latest Options Trading Trends in AbbVie ↗

May 14, 2024

Via Benzinga

(ABBV) - Analyzing AbbVie's Short Interest ↗

May 10, 2024

Via Benzinga

10 Stocks to Build a Dividend Portfolio With ↗

May 18, 2024

All 10 of these stocks pay reliable and growing dividends.

Via The Motley Fool

AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst ↗

May 17, 2024

Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine,...

Via Benzinga

7 Value Stocks to Buy and Hold for a Decade of Dominance ↗

May 17, 2024

Discover the enduring value of seven key value stocks to buy and hold in diverse sectors, presenting unparalleled opportunities.

Via InvestorPlace

Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for May 2024 ↗

May 16, 2024

Amid the strong run in the market, investors thinking about long-term goals should consider these strongly endorsed retirement stocks to buy.

Via InvestorPlace

Topics Retirement

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In ↗

May 14, 2024

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.

Via Benzinga

Topics Cannabis

3 Reasons to Buy AbbVie Stock on the Dip ↗

May 05, 2024

A little patience with the drugmaker should pay off.

Via The Motley Fool

$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today ↗

May 02, 2024

Via Benzinga

3 Magnificent Stocks That Are Passive Income Machines ↗

May 14, 2024

These three companies have track records that should please investors.

Via The Motley Fool

What Is the Dividend Payout for AbbVie Stock? ↗

May 13, 2024

The pharmaceutical company isn't just a quality healthcare holding. It's a compelling income investment as well.

Via The Motley Fool

Healthcare And Biotech Investing 101: What You Need To Know. ↗

May 13, 2024

Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of...

Via Talk Markets

Topics Stocks

Earn $1000 Every Month From These 3 Stocks ↗

May 11, 2024

All 3 companies pay growing dividends.

Via The Motley Fool

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever. ↗

May 11, 2024

These pharmaceutical companies are top-notch dividend growth stocks for the future.

Via The Motley Fool

3 Rock-Solid Dividend Stocks That Are Ideal for Retirees ↗

May 10, 2024

These are low-risk stocks with high yields.

Via The Motley Fool

Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare ↗

May 07, 2024

Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy.

Via InvestorPlace

AbbVie Tracking for New Highs in 2024

May 07, 2024

Future Dividend King AbbVie is tracking for new highs as the shift away from Humira-based business gains momentum with new treatments and acquisitions.

Via MarketBeat

Topics Earnings

3 Biotech Stocks to Double Your Money in the Next 24 Months ↗

May 06, 2024

The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates.

Via InvestorPlace

MarketBeat Week in Review – 4/29 - 5/3

May 04, 2024

Apple, Amgen, and a weak jobs report helped move the market higher as investors temporarily looked past the possibility of no interest rate cuts in 2024

Via MarketBeat

Topics Economy Stocks

7 Safe Haven Stocks That Can Withstand the Market’s Worst Meltdowns ↗

April 30, 2024

Safe haven stocks offer stability even during market fall in communication, financials, healthcare, energy and consumer staples.

Via InvestorPlace

Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher

April 30, 2024

After falling nearly 6% based on concerns about Humira sales, AbbVie stock is recovering, and bullish analyst sentiment is likely to push the stock higher

Via MarketBeat

Inflation-Proof Fortunes: 7 Dividend Aristocrats to Keep Your Wealth Growing ↗

April 30, 2024

These dividend aristocrat stocks can protect tired consumers from persistent inflation through dividends that outpace recent spikes.

Via InvestorPlace

Topics Economy

AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales ↗

April 29, 2024

The company is projected to bring in increasing sales through at least 2029.

Via Investor's Business Daily

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

92 93 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

AbbVie (NY:ABBV)

All News about AbbVie

Starting at $3.75/week.

Subscribe Today